Neurogene to Participate in Upcoming Investor Conferences
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neurogene (NASDAQ:NGNE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $50.00 price target on the stock.
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]